COVID-19 mRNA 疫苗对体弱老年人的有效性。
COVID-19 mRNA Vaccine Effectiveness against Elderly Frail People.
机构信息
Second Medical Clinic, School of Medicine, Ippokration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
Midwifery Department, School of Healthcare Sciences, University of West Macedonia, Koila, 50100 Kozani, Greece.
出版信息
Medicina (Kaunas). 2023 Jan 19;59(2):202. doi: 10.3390/medicina59020202.
Abstract
The frail, elderly population is often characterized by poor immunogenicity post COVID-19 mRNA vaccination. "Inflame-ageing" and "immune-senescence" are pathogenetic mechanisms that might explain this phenomenon. Complex interplay with cytokines and microbiota is also implicated in this inflammatory cascade. The abovementioned population, although very important from immunologic perspective, has barely been included in the mRNA vaccination clinical trials.
摘要
脆弱的老年人群在感染 COVID-19 信使核糖核酸（mRNA）疫苗后往往表现出较差的免疫原性。“炎症衰老”和“免疫衰老”是可能解释这一现象的发病机制。细胞因子和微生物群之间的复杂相互作用也与这一炎症级联反应有关。上述人群虽然从免疫学角度来看非常重要，但几乎没有被纳入 mRNA 疫苗临床试验。
相似文献
1
COVID-19 mRNA Vaccine Effectiveness against Elderly Frail People.COVID-19 mRNA 疫苗对体弱老年人的有效性。
Medicina (Kaunas). 2023 Jan 19;59(2):202. doi: 10.3390/medicina59020202.
2
Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.真实世界中衰弱老年人接受延长间隔和异源 COVID-19 mRNA 疫苗接种后的血清学反应（UNCoVER）：一项前瞻性观察队列研究的中期报告。
Lancet Healthy Longev. 2022 Mar;3(3):e166-e175. doi: 10.1016/S2666-7568(22)00012-5. Epub 2022 Feb 23.
3
Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents. frail 养老院居民接种 BNT162b2 mRNA 疫苗 6 个月后的安全性、有效性和免疫原性。
Drugs Aging. 2022 Jul;39(7):587-595. doi: 10.1007/s40266-022-00959-6. Epub 2022 Jul 7.
4
COVID-19 Vaccination for Frail Older Adults in Singapore - Rapid Evidence Summary and Delphi Consensus Statements.新加坡体弱老年人的 COVID-19 疫苗接种-快速证据摘要和德尔菲共识声明。
J Frailty Aging. 2022;11(2):236-241. doi: 10.14283/jfa.2022.12.
5
Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.BNT162b2 疫苗在体弱或残疾的疗养院居民中的免疫原性：COVID-A 研究。
J Am Geriatr Soc. 2021 Jun;69(6):1441-1447. doi: 10.1111/jgs.17153. Epub 2021 Apr 2.
6
Immunological responses to pneumococcal vaccine in frail older people.体弱老年人对肺炎球菌疫苗的免疫反应。
Vaccine. 2009 Mar 4;27(10):1628-36. doi: 10.1016/j.vaccine.2008.11.098. Epub 2008 Dec 17.
7
COVID-19 vaccination and frailty in older adults.老年人中的新冠病毒疫苗接种与虚弱状况
Arch Gerontol Geriatr. 2021 Sep-Oct;96:104487. doi: 10.1016/j.archger.2021.104487. Epub 2021 Jul 14.
8
Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.社区居住的自然暴露于流感的老年体弱人群中，流感疫苗诱导的抗体反应未受损害。
Front Immunol. 2018 Oct 24;9:2465. doi: 10.3389/fimmu.2018.02465. eCollection 2018.
9
Are vaccines against COVID-19 tailored to the most vulnerable people?针对新冠病毒的疫苗是为最脆弱人群量身定制的吗？
Vaccine. 2021 Apr 22;39(17):2325-2327. doi: 10.1016/j.vaccine.2021.03.066. Epub 2021 Mar 22.
10
Frailty is an independent determinant of COVID-19 vaccine hesitancy in the elderly: a cross-sectional study.衰弱是老年人对 COVID-19 疫苗犹豫不决的一个独立决定因素：一项横断面研究。
Cell Mol Biol (Noisy-le-grand). 2022 Apr 30;68(4):202-207. doi: 10.14715/cmb/2022.68.4.24.
引用本文的文献
1
Impairment of the Functional Status and Decrease in Albumin in Frail Older People After a COVID-19 Outbreak: A Descriptive Study in a Long-Term Care Facility in Chile.新冠疫情爆发后体弱老年人的功能状态受损及白蛋白水平下降：智利一家长期护理机构的描述性研究
Geriatrics (Basel). 2024 Dec 25;10(1):1. doi: 10.3390/geriatrics10010001.
2
Approach to COVID-19 in older adults and indications for improving the outcomes.老年人 COVID-19 的处理方法和改善预后的指征。
Ann Med. 2023;55(2):2265298. doi: 10.1080/07853890.2023.2265298. Epub 2023 Oct 15.
3
Real-World Safety of COVID-19 mRNA Vaccines: A Systematic Review and Meta-Analysis.新冠病毒mRNA疫苗的真实世界安全性：一项系统评价与荟萃分析
Vaccines (Basel). 2023 Jun 19;11(6):1118. doi: 10.3390/vaccines11061118.
本文引用的文献
1
Autopsy-based histopathological characterization of myocarditis after anti-SARS-CoV-2-vaccination.基于尸检的抗 SARS-CoV-2 疫苗接种后心肌炎的组织病理学特征。
Clin Res Cardiol. 2023 Mar;112(3):431-440. doi: 10.1007/s00392-022-02129-5. Epub 2022 Nov 27.
2
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.在完成初级接种程序和初始加强针接种后出现严重 COVID-19 结局：对英格兰、北爱尔兰、苏格兰和威尔士 3000 万人的全国前瞻性队列研究的汇总分析。
Lancet. 2022 Oct 15;400(10360):1305-1320. doi: 10.1016/S0140-6736(22)01656-7.
3
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.BNT162b2 mRNA疫苗在中国成年人中的免疫原性和安全性：一项2期随机临床试验。
Lancet Reg Health West Pac. 2022 Dec;29:100586. doi: 10.1016/j.lanwpc.2022.100586. Epub 2022 Sep 14.
4
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.mRNA COVID-19 疫苗接种后在成人随机试验中特别关注的严重不良事件。
Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31.
5
Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines in Adults Younger Than 75 Years in France.法国 75 岁以下成年人接种 COVID-19 疫苗后心肌梗死、中风和肺栓塞的风险。
Ann Intern Med. 2022 Sep;175(9):1250-1257. doi: 10.7326/M22-0988. Epub 2022 Aug 23.
6
Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study.描述 8 个国家/地区新冠病毒疫苗特殊关注不良事件的背景发生率：跨国网络队列研究。
BMJ. 2021 Jun 14;373:n1435. doi: 10.1136/bmj.n1435.
7
NF-κB, a culprit of both inflamm-ageing and declining immunity?核因子-κB，是炎症衰老和免疫力下降的罪魁祸首吗？
Immun Ageing. 2022 May 17;19(1):20. doi: 10.1186/s12979-022-00277-w.
8
Frailty and COVID-19 mRNA Vaccine Antibody Response in the COVID-19 Community Research Partnership.衰弱与 COVID-19 社区研究伙伴关系中 COVID-19 mRNA 疫苗抗体反应。
J Gerontol A Biol Sci Med Sci. 2022 Jul 5;77(7):1366-1370. doi: 10.1093/gerona/glac095.
9
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron.新冠病毒mRNA疫苗第四剂对奥密克戎毒株的效力
N Engl J Med. 2022 Apr 7;386(14):1377-1380. doi: 10.1056/NEJMc2202542. Epub 2022 Mar 16.
10
-Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic.第二卷：SARS-CoV-2 大流行两年后感染或 mRNA 疫苗接种、药物治疗和非药物管理后的免疫。
Medicina (Kaunas). 2022 Feb 17;58(2):309. doi: 10.3390/medicina58020309.
Zotero 插件